Na vakcíně proti borelioze se pracuje už dlouho, v USA se i prodávala, ale výrobce ji dobrovolně stáhnul kvůli závažným vedlejším účinkům a malé účinnosti: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2870557/
These findings suggested that, in patients with the DR4+ genotype, an immune response against OspA could translate into a cross-reactive autoimmune response. By implication, an OspA Lyme vaccine might result in autoimmunity in these genetically predisposed individuals. Although causality proved difficult to demonstrate, one study reported four male patients with the DR4+ genotype who developed autoimmune arthritis after receiving LYMErix™ vaccine.
Tak uvidíme, třeba se jim to napodruhé podaří lépe...